Cellerant Therapeutics is a clinical-stage biotechnology company whose focus is on the regulation of the hematopoietic system. Cellerant Therapeutics was founded in 2005 and is headquartered in San Carlos, California. Cellerant Therapeutics Inc. is a privately held, venture capital–backed corporation with investors including Allen & Company LLC, BD Ventures LLC, CX Venture Group, Eminent Venture Capital, GBR Investments LLC, MPM Capital, Rockbridge Growth Equity, and Sagamore Bioventures (formerly Novel Bioventures).

Cellerant Therapeutics is developing human stem cell and antibody therapies for oncology applications and blood related disorders. The lead product for Cellerant Therapeutics is CLT-008, which is currently associated with two Phase I clinical trials involving patients with hematological malignancies. Cellerant has also produced a cancer stem cell (CSC) antibody discovery program that is focused on ...